Why is Titan Biotech Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0.04 times
2
Poor long term growth as Operating profit has grown by an annual rate -7.23% of over the last 5 years
3
Positive results in Sep 25
- NET SALES(Q) Highest at Rs 54.35 cr
- PBDIT(Q) Highest at Rs 9.32 cr.
- PBT LESS OI(Q) Highest at Rs 7.90 cr.
4
With ROE of 13.9, it has a Very Expensive valuation with a 4.7 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 9.25%, its profits have fallen by -8.8%
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
6
Consistent Returns over the last 3 years
- Along with generating 9.25% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
How much should you hold?
- Overall Portfolio exposure to Titan Biotech should be less than 10%
- Overall Portfolio exposure to Specialty Chemicals should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Titan Biotech for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Titan Biotech
9.25%
0.15
59.69%
Sensex
4.83%
0.41
11.83%
Quality key factors
Factor
Value
Sales Growth (5y)
9.46%
EBIT Growth (5y)
-7.23%
EBIT to Interest (avg)
26.04
Debt to EBITDA (avg)
0.26
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
1.22
Tax Ratio
25.02%
Dividend Payout Ratio
6.65%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
25.43%
ROE (avg)
21.23%
Valuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
40
Price to Book Value
4.67
EV to EBIT
33.90
EV to EBITDA
28.50
EV to Capital Employed
4.56
EV to Sales
4.49
PEG Ratio
NA
Dividend Yield
0.21%
ROCE (Latest)
13.46%
ROE (Latest)
13.86%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
Technical Movement
10What is working for the Company
NET SALES(Q)
Highest at Rs 54.35 cr
PBDIT(Q)
Highest at Rs 9.32 cr.
PBT LESS OI(Q)
Highest at Rs 7.90 cr.
PAT(Q)
Highest at Rs 7.76 cr.
EPS(Q)
Highest at Rs 9.39
-3What is not working for the Company
ROCE(HY)
Lowest at 16.04%
DEBTORS TURNOVER RATIO(HY)
Lowest at 5.88 times
Loading Valuation Snapshot...
Here's what is working for Titan Biotech
Net Sales - Quarterly
Highest at Rs 54.35 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 54.35 cr has Grown at 36.25%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 9.32 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 7.90 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 7.90 cr has Grown at 23.44%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 7.76 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 9.39
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Titan Biotech
Debtors Turnover Ratio- Half Yearly
Lowest at 5.88 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio






